Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Guelph

$29,000.00

homeostatic regulation of erythrocytes

FY 2018-19

Summary
The hematopoietic hormone erythropoietin (EPO) is the main regulator of erythropoiesis; it stimulates the proliferation and differentiation of erythroid precursor cells. For over half a century, the kidney has been regarded as the primary site for EPO production. In 1957, Jacobson et al. used classical organ ablation experiments to conclude that the kidney is the site of EPO production in response to extreme (non-survivable) hypoxia (reduction in inspired oxygen). Subsequent studies were generally confined to confirming that the kidney produces EPO rather than exploring whether other tissues do so. We have established the kidney is not the sole producer of EPO in response to hypoxia. Surprisingly, although erythropoiesis is necessary to correct for reductions in circulating erythrocytes, no studies have performed an unbiased examination of the form(s) and tissue site(s) of EPO production. While the kidney does produce EPO, we have exciting preliminary data that the major form of EPO produced by the kidney is a novel splice variant. Further, we have identified a new tissue site for EPO production in response to low circulating erythrocytes that also produce their own unique splice variant of EPO. This poses the questions as to why there are two novel splice variants of EPO and what is the physiological relevance of this built-in redundancy that is specific to perturbations in circulating erythrocytes?*Multiple isoforms of EPO are present in normoxic human blood, raising the possibility of different sites of production and/or differential affinities for the EPO receptor at target organs/tissues. While multiple charge variants of EPO have been observed, whether these variants arise as a result of splice variants remains to be investigated. Thus, the specific questions this application aims to address are whether the different forms of EPO are produced by and for specific target organs and/or to elicit specific fundamental physiological responses?*EPO is no longer recognized as just a hematopoietic cytokine. EPO is important for organogenesis, is an inotropic agent, induces cell proliferation and confers profound cytoprotection against cellular stress. Thus, different forms of EPO are very likely of physiological importance for receptor specificity and downstream pathway activation. The objective of our research program is to uncover fundamental knowledge about EPO forms that are produced in various tissues to correct for perturbations in circulating erythrocytes. Further, we will study the ability of novel splice variants on hematopoiesis, contractility, proliferation and cytoprotection as well as their tissue source. Our research program seeks to advance the field of the basic physiological mechanism regulating erythrocyte homeostasis and provide a better understanding of the role and the impact of these novel splice variants on these important responses.*
Program
Discovery Grants Program - Individual
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2018-05626
Name nom
Simpson, Jeremy
Department département
Human Health and Nutritional Sciences
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
29000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5102
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Inter-cellular communication
Research subject fr
Communication inter-cellulaire
Partie
1
Nb partie
5
Application title
homeostatic regulation of erythrocytes
Keyword
NSERC
Application summary
The hematopoietic hormone erythropoietin (EPO) is the main regulator of erythropoiesis; it stimulates the proliferation and differentiation of erythroid precursor cells. For over half a century, the kidney has been regarded as the primary site for EPO production. In 1957, Jacobson et al. used classical organ ablation experiments to conclude that the kidney is the site of EPO production in response to extreme (non-survivable) hypoxia (reduction in inspired oxygen). Subsequent studies were generally confined to confirming that the kidney produces EPO rather than exploring whether other tissues do so. We have established the kidney is not the sole producer of EPO in response to hypoxia. Surprisingly, although erythropoiesis is necessary to correct for reductions in circulating erythrocytes, no studies have performed an unbiased examination of the form(s) and tissue site(s) of EPO production. While the kidney does produce EPO, we have exciting preliminary data that the major form of EPO produced by the kidney is a novel splice variant. Further, we have identified a new tissue site for EPO production in response to low circulating erythrocytes that also produce their own unique splice variant of EPO. This poses the questions as to why there are two novel splice variants of EPO and what is the physiological relevance of this built-in redundancy that is specific to perturbations in circulating erythrocytes?*Multiple isoforms of EPO are present in normoxic human blood, raising the possibility of different sites of production and/or differential affinities for the EPO receptor at target organs/tissues. While multiple charge variants of EPO have been observed, whether these variants arise as a result of splice variants remains to be investigated. Thus, the specific questions this application aims to address are whether the different forms of EPO are produced by and for specific target organs and/or to elicit specific fundamental physiological responses?*EPO is no longer recognized as just a hematopoietic cytokine. EPO is important for organogenesis, is an inotropic agent, induces cell proliferation and confers profound cytoprotection against cellular stress. Thus, different forms of EPO are very likely of physiological importance for receptor specificity and downstream pathway activation. The objective of our research program is to uncover fundamental knowledge about EPO forms that are produced in various tissues to correct for perturbations in circulating erythrocytes. Further, we will study the ability of novel splice variants on hematopoiesis, contractility, proliferation and cytoprotection as well as their tissue source. Our research program seeks to advance the field of the basic physiological mechanism regulating erythrocyte homeostasis and provide a better understanding of the role and the impact of these novel splice variants on these important responses.*